Ross Osborn
Stock Analyst at Cantor Fitzgerald
(3.07)
# 1,312
Out of 4,711 analysts
95
Total ratings
40.24%
Success rate
2.25%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NNOX Nano-X Imaging | Maintains: Overweight | $11 → $12 | $6.76 | +77.51% | 10 | Dec 6, 2024 | |
| PRE Prenetics Global | Reiterates: Overweight | $9 | $5.65 | +59.43% | 6 | Dec 4, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Overweight | $3 → $2 | $0.78 | +156.08% | 4 | Nov 15, 2024 | |
| ELUT Elutia | Reiterates: Overweight | $10 | $4.84 | +106.61% | 9 | Nov 15, 2024 | |
| NYXH Nyxoah | Reiterates: Overweight | $16 | $8.01 | +99.75% | 4 | Nov 5, 2024 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $14 | $12.11 | +15.61% | 2 | Oct 23, 2024 | |
| LMAT LeMaitre Vascular | Initiates: Neutral | $96 | $92.12 | +4.21% | 1 | Oct 15, 2024 | |
| NPCE NeuroPace | Reiterates: Overweight | $18 | $11.53 | +56.11% | 4 | Aug 14, 2024 | |
| RCEL AVITA Medical | Reiterates: Overweight | $21 | $11.77 | +78.42% | 9 | Aug 9, 2024 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $3.5 | $1.97 | +77.66% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $9.10 | +20.88% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.68 | +269.88% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $44 | $33.68 | +30.64% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $5.15 | +35.92% | 4 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.58 | +153.16% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $6.68 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.3 | $0.77 | +328.57% | 5 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.05 | +63.93% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 | $13.25 | +88.68% | 7 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $12 | $15.64 | -23.27% | 2 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.58 | +1,379.38% | 2 | Aug 18, 2023 |
Nano-X Imaging
Dec 6, 2024
Maintains: Overweight
Price Target: $11 → $12
Current: $6.76
Upside: +77.51%
Prenetics Global
Dec 4, 2024
Reiterates: Overweight
Price Target: $9
Current: $5.65
Upside: +59.43%
Lucid Diagnostics
Nov 15, 2024
Maintains: Overweight
Price Target: $3 → $2
Current: $0.78
Upside: +156.08%
Elutia
Nov 15, 2024
Reiterates: Overweight
Price Target: $10
Current: $4.84
Upside: +106.61%
Nyxoah
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $8.01
Upside: +99.75%
CVRx, Inc.
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $12.11
Upside: +15.61%
LeMaitre Vascular
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $92.12
Upside: +4.21%
NeuroPace
Aug 14, 2024
Reiterates: Overweight
Price Target: $18
Current: $11.53
Upside: +56.11%
AVITA Medical
Aug 9, 2024
Reiterates: Overweight
Price Target: $21
Current: $11.77
Upside: +78.42%
Pacific Biosciences of California
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.97
Upside: +77.66%
Aug 1, 2024
Reiterates: Overweight
Price Target: $11
Current: $9.10
Upside: +20.88%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.68
Upside: +269.88%
May 15, 2024
Reiterates: Overweight
Price Target: $44
Current: $33.68
Upside: +30.64%
May 14, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $5.15
Upside: +35.92%
May 3, 2024
Maintains: Overweight
Price Target: $3 → $4
Current: $1.58
Upside: +153.16%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $6.68
Upside: -
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $0.77
Upside: +328.57%
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.05
Upside: +63.93%
Feb 27, 2024
Maintains: Overweight
Price Target: $25
Current: $13.25
Upside: +88.68%
Jan 19, 2024
Reiterates: Overweight
Price Target: $12
Current: $15.64
Upside: -23.27%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.58
Upside: +1,379.38%